Rexahn Pharmaceuticals (RNN) 0.59 0.00

Rexahn Pharmaceuticals
(RNN) 0.59 0.00

Last Trade:	0.408	Day Range:	0.38 - 0.4401
Trade Time:	06:05PM	52wk Range:	0.342 - 1.36
Prev. Close:	0.408	Market Cap:	38.9M
Open:	0.41	Div Yield:
Volume:	175296	PE:
EPS:	-0.09

The Latest On RNN

Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA 5/8/12 8:02am

Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds 4/30/12 8:04am

Earnings Scheduled For March 20 3/20/12 4:08am

Earnings Scheduled For March 16 3/16/12 3:51am

Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117 3/13/12 8:02am

Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds 1/25/12 9:00am

Benzinga's Microcap Movers for Wednesday January 18, 2012 1/18/12 9:04pm

Rodman & Renshaw Changes Rating on Rexahn Pharmaceuticals to Market Perform 1/18/12 1:44pm

Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors 1/18/12 9:02am

Rexahn Pharmaceuticals Provides Key Goals for 2012 1/17/12 9:03am

Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin as Treatment for Major Depressive Disorder 11/4/11 8:04am

Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds 10/12/11 8:00am

Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA 5/8/12

Rexahn Pharmaceuticals Issued Japanese Patent for New Anti-cancer Compounds 4/30/12

Earnings Scheduled For March 20 3/20/12

Earnings Scheduled For March 16 3/16/12

Rexahn Pharmaceuticals Enrolls First Subject in Exploratory Phase I Clinical Study of RX-3117 3/13/12

Rexahn Pharmaceuticals Publishes New Preclinical Data for Quinoxalinyl-Piperazine Compounds 1/25/12

Benzinga's Microcap Movers for Wednesday January 18, 2012 1/18/12

Rodman & Renshaw Changes Rating on Rexahn Pharmaceuticals to Market Perform 1/18/12

Rexahn Pharmaceuticals Secures Approval in Europe to Conduct a First-in-Human Trial of RX-3117 in Solid Tumors 1/18/12

Rexahn Pharmaceuticals Provides Key Goals for 2012 1/17/12

Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin as Treatment for Major Depressive Disorder 11/4/11

Rexahn Pharmaceuticals Granted US Patent for Novel Anti-cancer Isoquinolinamine Compounds 10/12/11

Benzinga's Microcap Movers for Wednesday January 18, 2012 1/18/12

Companies with CEO Buys of Over 50k Shares in April 2011 4/28/11

Mid-Day Market Movers (RNN, VPF, BFSB, AHC) 6/22/10

Rodman & Renshaw Changes Rating on Rexahn Pharmaceuticals to Market Perform 1/18/12

Trade RNN
NOW!

Partner Headlines

Insiders Trading FURX, MELI, FRP 5/23/11

6 Stocks With Big Insider Buying 4/12/11

Insiders Trading RNN, LULU, KYN, GES 4/6/11

Biotech Mailbag: BIO CEO Wrap 2/18/11

Biotech Stock Mailbag: Protalix BioTherapeutics 2/11/11

Rexahn Higher on Deja Vu Stock Promotion 2/8/11

6 Penny Stocks for the Biotech Boom 2/1/11

Genoptix, Clinical Data: Small-Cap Winners 1/24/11

Wendy's/Arby's, BioLase: Small-Cap Winners 1/20/11

Stocks Under $5 Least Likely to Go Bankrupt 9/16/10

Rodman Rambles: The Biotech Dreck 9/15/10

$5 Stocks Least Likely to Declare Bankruptcy 8/5/10

Press Releases

Get the latest RNN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Rexahn Pharmaceuticals stock price.

Rexahn Pharmaceuticals by YCharts

Rexahn Pharmaceuticals (RNN) 0.59 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On RNN

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social